Breaking News, Promotions & Moves

Genesis Appoints CRO Business Executive

Dr. Olesia Buiakova joins the company as chief scientific officer with over two decades of industry experience

Genesis Drug Discovery & Development (GD3) the contract research organization of Genesis Biotechnology Group, has announced the appointment of Olesia Buiakova, M.D., Ph.D., the current chief scientific officer of Invivotek, as its new chief scientific officer.    In this capacity, as an expansion of Dr. Buiakova’s current role, she will be responsible for managing the entire integrated GD3 portfolio of drug discovery services from target validation and assay development to iden...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters